Biotinoyl Tripeptide-1 (Biotinyl-GHK) for Hair: Evidence & Safety

Biotinoyl Tripeptide-1 (biotinyl-GHK; Biotin-Gly-His-Lys-OH) is a synthetic cosmetic peptide that bolts biotin onto the well-studied matrikine tripeptide GHK to create a follicle-targeted "anchoring" active, best known as the lead component of the patented Procapil complex.6 Its popularity in hair-care serums is large; its proof as an isolated molecule is not. This monograph separates the combination-product human data from the molecule's mechanistic claims.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Biotinoyl Tripeptide-1 is a topical cosmetic peptide, not an FDA-approved drug. Dosing and formulation figures are reported strictly as seen in the published literature and product dossiers, for completeness. Consult a licensed dermatologist before any health decision.

What is Biotinoyl Tripeptide-1 and how does it work?

Chemically, biotinyl-GHK is the conjugate of biotin (vitamin B7) to the tripeptide GHK (glycyl-L-histidyl-L-lysine), sequence Biotin-Gly-His-Lys-OH, molecular formula C₂₄H₃₈N₈O₆S, molecular weight about 566.7 g/mol, CAS 299157-54-3, INCI "Biotinoyl Tripeptide-1."45 It is a white, water-soluble, cosmetic-grade powder trade-named as a component of Procapil and, in lash products, as Widelash. The design intent is mechanistic: the GHK moiety is a copper-affinity matrikine with tissue-repair and extracellular-matrix-remodeling activity, while the biotin moiety is meant to increase keratin affinity and retention at keratin-rich follicular structures versus free GHK or free biotin.7 You can view the molecule's reference chemistry on PubChem.

The signature claimed mechanism — entirely in-vitro and dossier-level, hence grade C for the molecule alone — is reinforcing the follicle's anchorage in the dermis. Per a 2025 International Journal of Trichology review, biotinyl-GHK anchors hair via adhesion proteins including vimentin, desmogleins, desmocollins, laminin-5 and collagen IV, and stimulates keratinocyte multiplication, targeting failing anchorage within the dermal papilla.1 Supplier and mechanistic summaries concur that it stimulates collagen IV and laminin-5 synthesis at the dermal-epidermal junction, strengthening the mechanical anchoring of the hair shaft and raising the traction threshold needed to dislodge a hair — i.e., reducing premature shedding.6 No formal human pharmacokinetic data exist; as a water-soluble roughly 567-Da peptide used topically, transdermal penetration to the hair bulb is the limiting step, and the biotin conjugation is rationalized as improving substantivity rather than producing systemic absorption.7

What is the human evidence by indication?

The critical framing: no published randomized controlled trial tests biotinyl-GHK in isolation. All human evidence is for multi-ingredient formulations in which it is one active, so the findings below describe the formulation, with biotinyl-GHK as a contributor. Direction of effect is consistent and favorable, but every dataset is small, mostly open-label, and frequently industry-linked.

The single true randomized human dataset is Karaca and Akpolat's 24-week trial, which randomized 106 adult males with androgenetic alopecia to an RCP blend (Redensyl + Capixyl + Procapil) or 5% minoxidil. By researcher score, improvement favored RCP (64.7% vs 25.5%); by photographic evaluation, 88.9% vs 60%.1 The crucial caveat is that this is a three-active blend, so the result cannot be attributed to biotinyl-GHK specifically — and a cosmetic blend beating the minoxidil gold standard warrants cautious interpretation given small size and potential sponsorship bias. Garre and colleagues' 6-month open-label study in 56 AGA and telogen-effluvium patients found significant increases in total and anagen hair counts plus high patient-reported satisfaction, but had no placebo arm.3 The 2025 MDPI trial by Voiculescu and Lupu compared a Procapil spray alone versus spray plus oral capsules in 48 AGA patients, finding gains in density, shaft thickness and anagen/telogen ratio in both arms — and its authors explicitly state none of this rises to the minoxidil/finasteride evidence level, calling for randomized double-blind placebo-controlled trials.2 Eyelash, eyebrow and skin-anti-aging uses remain grade C-D — mechanistic extrapolation and marketing, with no controlled efficacy trials identified.6

What doses and formulations appear in the literature?

Reported strictly as information, not a protocol. The route is topical only — scalp lotion, serum or spray, or a lash/brow serum; no injectable or oral use of the isolated peptide is described.1 Procapil is typically used around 3% in the scalp lotions in the cited trials, though finished cosmetic serums vary and rarely disclose the exact biotinyl-GHK percentage.1 Reported regimens are once or twice daily for 3 to 6 months, the window over which trichoscopic changes were measured.2 As a raw material it is a water-soluble powder stored cold and formulated into aqueous or alcoholic vehicles.6 The combinations matter: clinical benefit was demonstrated for the blend — with apigenin and oleanolic acid, sometimes plus adenosine, diaminopyrimidine oxide, biotin and Ginkgo — not the isolated peptide.

How safe is it, and what is the 2026 regulatory status?

Across the Procapil pilot, the 56-patient open-label study and the comparator trials, no significant adverse events were reported, and authors describe a favorable side-effect profile positioning these agents as options for patients intolerant of minoxidil or finasteride.1 The honest limitation: no study has specifically evaluated the standalone topical safety of biotinyl-GHK; the reassuring record reflects years of cosmetic use without reported adverse effects, which is encouraging but is not a dedicated safety dataset.10 Theoretical risks are limited to local contact irritation or hypersensitivity to the active or vehicle excipients — apply to intact scalp skin. There is no evidence of systemic absorption, angiogenic or tumor-promoting risk for the topical route, and unlike GH-axis peptides it has no anabolic or hormonal systemic mechanism. One practical caution for the biotin component is that high systemic biotin can interfere with certain immunoassays, though the contribution from a topical product is expected to be negligible.12

Legally it sits in the low-risk cosmetic-ingredient lane. The FDA regulates biotinyl-GHK as a cosmetic ingredient, not an approved drug; cosmetics are not subject to FDA pre-market approval, and topical hair-conditioning claims keep it in the cosmetic lane rather than the OTC-drug monograph lane occupied by minoxidil.11 It is not a compounded injectable peptide and was therefore unaffected by the 2023-2025 FDA Category-2 bulk-substances actions that swept up injectable research peptides such as BPC-157 — those rulings concern compounding bulk drug substances, a category this topical cosmetic does not enter. For athletes, biotinyl-GHK is not on the WADA Prohibited List, being a topical cosmetic peptide with no GH-secretagogue, anabolic or systemic hormonal activity.13

Bottom line. Biotinoyl Tripeptide-1 is a well-tolerated topical whose anchoring mechanism is biologically reasonable (grade C in isolation) and which, only as part of the Procapil blend, has produced modest, directionally consistent improvements in hair density, anagen/telogen ratio and shedding (grade B for the combination). What is unresolved: isolated-molecule efficacy, optimal concentration, long-term and pregnancy safety, and how much of the blend's effect actually traces to oleanolic acid's DHT inhibition versus the peptide. Reasonable expectation: a gentle daily adjunct for early or mild thinning, or for the minoxidil-intolerant — not a stand-alone treatment for advanced hair loss. Informational only; not medical advice.